Revolution Medicines

October 17, 2019

Triple meeting – clinical data, and competition, loom for Mirati

Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.

July 10, 2019

Redx sells another asset to keep the lights on

The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.

June 04, 2019

Asco 2019 – KRAS chase heats up with Amgen data

Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.

Revolution Medicines

Triple meeting – clinical data, and competition, loom for Mirati

Redx sells another asset to keep the lights on

Asco 2019 – KRAS chase heats up with Amgen data

Latest Reports

Vantage Pharma, Biotech & Medtech Half-Year Review 2019

Vantage Pharma, Biotech and Medtech 2018 in Review

Editor's Picks

Shock revelation sees Biogen erase its aducanumab losses

Vertex’s double cystic fibrosis surprise

Bristol might play a role in front-line lung cancer after all

Bloated on arrival? Biotech's weightiest new issues

Uncovering biopharma’s hidden treasures